Retatrutide Isn't FDA-Approved Yet — What That Means for the Cancer Questions Around GLP-1 Drugs

Claim: A not-yet-approved drug is already being used by "millions," and it's "theoretically the greatest"

A widely shared Instagram reel from the account @theglp1.era makes a bold claim. It says retatrutide — a drug that "isn't approved yet" — is already used by "millions." It calls the drug "theoretically the greatest" weight-loss medication available.

Instagram's caption cuts off before the full claim. Cancer Explained could not view the rest of the post, so we can't verify or repeat whatever follows. What we can check is the part that's visible: retatrutide's approval status, and what's actually known about this drug class and cancer.

Retatrutide is an experimental drug from Eli Lilly. It acts on three hormone receptors at once: GLP-1, GIP, and glucagon. This makes it a "triple agonist." That's different from single-target drugs like semaglutide (Ozempic, Wegovy) or dual-target tirzepatide (Mounjaro, Zepbound).

As of this writing, retatrutide has not received FDA approval. Its Phase 3 trial program (TRIUMPH) has been reporting results. Two of its trials reached primary completion in early-to-mid 2026. But full approval and public sale haven't happened yet. In the meantime, unauthorized sellers have already begun offering retatrutide. Eli Lilly is suing some of these sellers. This matches the reel's claim that people are getting the drug before approval, even if "millions" is hard to confirm.

What's actually known about GLP-1 drugs and cancer

A cancer information site's job differs from a general health outlet here. The interesting question isn't just "does it work for weight loss." It's "what do we know about this drug class and cancer risk," in both directions.

The thyroid signal. Semaglutide's FDA label carries a boxed warning — the FDA's strongest kind. It's based on rodent studies. There, the drug caused thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). It's still unknown if semaglutide causes these tumors in humans. No clear signal has shown up in human trial and safety data so far.

Because of the rodent findings, semaglutide is off-limits for anyone with a personal or family history of medullary thyroid carcinoma. The same is true for the inherited condition multiple endocrine neoplasia type 2 (MEN2). Other drugs in this hormone family carry similar warnings. Regulators will likely check retatrutide for the same rodent signal as its safety data grows. But that human-use data doesn't exist yet for retatrutide, the way it does for semaglutide.

The other side: obesity and cancer risk. Obesity is one of the most well-proven, changeable cancer risk factors there is. NCI links higher body fat to a higher risk of at least 13 cancer types. That list includes postmenopausal breast, endometrial, colorectal, kidney, liver, pancreatic, and ovarian cancers. The link runs through things like excess estrogen, high insulin, and inflammation.

That's part of why researchers study whether GLP-1 drugs, through major weight loss, might lower the rate of these cancers. One large study of people with type 2 diabetes found lower risk. Those on GLP-1 drugs had lower risk of 10 of 13 obesity-related cancers than people on other diabetes treatments. But this evidence is still early and mixed. A review of randomized trials found no link between GLP-1 drugs and stomach or gut cancer risk. Studies like these can suggest a pattern. They can't prove the drug itself caused the lower risk. People who succeed on these drugs may differ in other health-related ways from those who don't.

The bigger picture

None of this research exists for retatrutide obtained outside FDA oversight. A drug not yet approved hasn't completed the full safety review. Getting it through gray-market sellers adds more uncertainty.

The FDA has already documented real harm from unapproved versions of similar GLP-1 drugs. Nearly 1,000 adverse event reports tie to compounded semaglutide. Over 700 tie to compounded tirzepatide. Some needed hospital care. Dosing errors come from unclear instructions. Quality problems come from bad storage or fake labeling. Whatever retatrutide's long-term profile turns out to be, it's still being written through finished trials and FDA review — not through a product bought before either is done.

For a cancer-information audience, the honest summary is this. The thyroid tumor warning on this drug class is real, but its meaning for humans is still unconfirmed. The chance that these drugs lower obesity-linked cancer risk is a real, active research question — not a settled fact. And using an unapproved, unregulated version of any drug in this class, retatrutide included, means going without the safety data that would normally guide that choice.

Sources

• FDA — Medications Containing Semaglutide Marketed for Type 2 Diabetes or Weight Loss
• National Cancer Institute — Obesity and Cancer Fact Sheet
• Instagram (@theglp1.era), reel referenced in this article: https://www.instagram.com/reel/Db28CwRDp2K/ (caption partially inaccessible behind Instagram's login wall)

How this article was prepared

An AI-assisted editorial system helped prepare this page. No named medical reviewer has reviewed it unless one is listed.

Cancer Explained is published by the National Cancer Information Foundation. It is not medical advice and does not suggest a test or treatment.

See an error, old source, or unclear wording? Tell us.